PolyPid (FRA:2PV) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:2PV PolyPid Ltd FRA:2PV
14 GF Score
Price €3.99
! 1 Warning Sign
View Full Analysis

What is PolyPid Notes Receivable?

PolyPid FRA:2PV -9.43% 14 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:2PV with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

PolyPid's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

PolyPid Notes Receivable Historical Data

* Premium members only.

The historical data trend for PolyPid's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPid Notes Receivable Chart

PolyPid Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PolyPid Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2PV
14GF Score
PolyPid Ltd FRA:2PV
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPid Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
PolyPid (FRA:2PV) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PolyPid and its competitors.
Is PolyPid's Notes Receivable too high?
PolyPid's current Notes Receivable is €0.00 Mil. Overall, PolyPid has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does PolyPid's Notes Receivable compare to LONA and ANIX?
PolyPid's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PolyPid and its competitors. PolyPid's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPid stock overvalued right now?
PolyPid (FRA:2PV) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. PolyPid's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For PolyPid (FRA:2PV), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PolyPid Business Description

Other Exchanges PYPD:USA
Address 18 Hasivim Street, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
14GF Score

Get the complete analysis for FRA:2PV

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price